Internal Medicine, Endocrinology, Diabetes, & Metabolism · Bourbonnais, IL
NPI
1942339932
Since 2007
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
100 Fitness Dr
Bourbonnais, IL, 60914
Phone (815) 936-8909
Groups this clinician bills Medicare through
Medicare paid, 2024
$75K
1,649 services
Medicare patients, 2024
391
Average age 72
Drug cost, 2024
$2.2M
4,937 prescriptions
Company payments, 2025
$107
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rachel N Shell was code 99214 (office e&m - established), 953 times for 382 patients. In total Rachel N Shell billed 1,649 services in 6 codes, and Medicare paid $75K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-05-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 953 | 382 | $65.07 | $62K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 397 | 268 | $12.44 | $4,939 |
| 95251 Test - Miscellaneous | Office | 276 | 102 | $24.07 | $6,644 |
| 99204 Office E&M - New | Office | 11 | 11 | $93.69 | $1,031 |
| 99213 Office E&M - Established | Office | 11 | 11 | $15.50 | $171 |
By year: 2022 $74K for 1,376 services; 2023 $72K for 1,207 services; 2024 $75K for 1,649 services.
Medicare prescription drug claims, 2024
In 2024, the drug Rachel N Shell prescribed most often to Medicare patients was Levothyroxine Sodium, with 996 prescriptions and refills. In total Rachel N Shell wrote 4,937 Medicare prescriptions that cost $2.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 996 | 2,345 | 200 | $8,002 |
| Ozempic Semaglutide | 290 | 505 | 69 | $463K |
| Metformin Hcl Er Metformin Hcl | 251 | 702 | 62 | $2,621 |
| Glipizide Er Glipizide | 190 | 487 | 47 | $3,447 |
| Trulicity Dulaglutide | 173 | 272 | 33 | $254K |
| Synthroid Levothyroxine Sodium | 173 | 399 | 38 | $15K |
| Jardiance Empagliflozin | 158 | 380 | 38 | $222K |
| Metformin Hcl Generic | 151 | 419 | 44 | $1,026 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 137 | 345 | 47 | $15K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 122 | 286 | 41 | $21K |
| Methimazole Generic | 107 | 219 | 21 | $1,309 |
| Mounjaro Tirzepatide | 103 | 125 | 19 | $128K |
| Rosuvastatin Calcium Generic | 96 | 253 | 31 | $788 |
| Humalog Kwikpen U-100 Insulin Lispro | 95 | 206 | 31 | $44K |
| Farxiga Dapagliflozin Propanediol | 93 | 189 | 23 | $104K |
Brand drugs: 2,494 claims; generic drugs: 1,986 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rachel N Shell $107 ($107 in general payments such as food, travel and fees) from 6 companies. The largest payer was Ascensia Diabetes Care Us Inc. with $22.42.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.